Compositions and methods for targeted delivery to cells
US-2024390271-A1 · Nov 28, 2024 · US
Use of Pateamine A for the treatment of age-related muscle wasting
US9358249B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9358249-B2 |
| Application number | US-200913129539-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 18, 2009 |
| Priority date | Nov 18, 2008 |
| Publication date | Jun 7, 2016 |
| Grant date | Jun 7, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
In certain embodiments this invention pertains to the discovery that inhibition of the expression and/or activity of eukaryotic initiation factor 4A (eIF4A) inhibits the aging process. Accordingly, in certain embodiments, methods are provided for inhibiting/slowing aging. The methods typically involve administering to a mammal an agent that inhibits the expression and/or activity of eukaryotic initiation factor 4A (eIF4A) in an amount sufficient to inhibit expression or activity of EIF4A, where the agent is not resveratrol.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of slowing age-related muscle wasting in a human exhibiting age-related frailty characterized by sarcopenia, said method comprising: administering to said human a pharmaceutical formulation comprising pateamine A in an amount sufficient to inhibit expression or activity of EIF4A and to reduce the progression of said age-related muscle wasting. 2. The method according to claim 1 , wherein said pateamine A is administered in a unit dosage formulation. 3. The method according to claim 1 , wherein said agent is combined with an excipient suitable for administration to a human.
Assignees
Inventors
Classifications
Free radical scavengers or antioxidants · CPC title
involving cells · CPC title
stimulating, promoting or activating activity · CPC title
Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title
- A61K31/7105Primary
Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9358249B2 cover?
- In certain embodiments this invention pertains to the discovery that inhibition of the expression and/or activity of eukaryotic initiation factor 4A (eIF4A) inhibits the aging process. Accordingly, in certain embodiments, methods are provided for inhibiting/slowing aging. The methods typically involve administering to a mammal an agent that inhibits the expression and/or activity of eukaryotic …
- Who is the assignee on this patent?
- Huang Jing, Hao Rui, Lomenick Brett Eugene, and 3 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/7105. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 07 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).